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1 Contributed equally to this work.The addition of N-glycans to clinically used proteins enhances their therapeutic features. Here we
report the design of a novel peptide tag with an unnatural N-glycosylation site, which may increase
the N-glycan content of generally any protein. The designed GlycoTags were attached to A1AT, EPO
and AGP and constructs were expressed in HEK293 or CHO cells. Hereby we could prove that the
attached unnatural N-glycosylation site is decorated with complex-type N-glycans and that the
spacer as well as the C-terminal ‘‘tail’’ sequence are critical for the usage of the novel N-glycosylation
site. This demonstrates that the novel GlycoTag is a convenient tool to provide proteins with extra N-
glycan moieties by simply adding a peptide tag sequence as small as 22 amino acids.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
In the last years, the importance of recombinantly expressed
therapeutical (glyco)proteins – named biotherapeutics – has
remarkably increased. These include cytokines like erythropoietin,
hormones or numerous antibodies that have been developed for
the treatment of cancer or inﬂammation [1]. It is well known that
the carbohydrate moieties of biotherapeutics play a key role in
inﬂuencing the stability as well as the biological function of glyco-
proteins [2]. In particular, the circulatory half-life of serum glyco-
proteins is directly depending on the amount of sialic acids that
they contain; desialylated glycoproteins are cleared from the circu-
lation by binding to the asialoglycoprotein receptor and/or man-
nose receptor [2–4].
The inﬂuence of glycan moieties on the activity and half-life of
proteins was impressively illustrated by a modiﬁed erythropoietin
(EPO) molecule. This genetically engineered Darbepoietin alfa
carries two additional N-glycans besides three natural N-glycans
and one O-glycan and exhibits a threefold longer half-life than
the natural EPO [5]. Interestingly, Darbepoietin alfa has a fourfold
lower receptor binding activity. However, the activity is sufﬁcientchemical Societies. Published by E
ha-1 acid glycoprotein; EPO,
ignal peptide; GT, GlycoTag;
p).to activate the EPO receptor, so that the overall potency in increas-
ing the hematocrit is about 13-fold more potent than the natural
EPO when administered once weekly [5]. Thus, the glycan moieties
of recombinant proteins are ideal targets for the design of im-
proved biotherapeutics.
The introduction of additional N-glycosylation sites into the
coding sequence of a protein may lead to its inactivity because
the expressed N-glycans or the mutated amino acids may change
the steric properties or the three-dimensional structure of the pro-
tein. Therefore the introduction of a peptide tag constituted of an
N-glycosylation site may overcome these disadvantages as the ma-
ture amino acid sequence of the protein is not changed. Further-
more the GlycoTag technology reported here presents the
advantage that it can potentially be applied to any protein unless
the N- or C-terminus is hidden inside the protein structure.
However, the utilization of an N-glycosylation motif at the C-
terminus of a protein by the oligosaccharyl transferase complex
(OST) depends on the structural features of the C-terminal amino
acid sequence. A statistical study based on a data set of occupied
and non-occupied N-glycosylation sites showed that non-occupied
sites are found more frequently towards the C-terminal end [6].
This was later supported by a study in which the N-glycosylation
efﬁciency was reduced if the C-terminus consisted of less than
68 amino acids [7]. Furthermore, an in vitro transcription/transla-
tion study of the Escherichia coli inner membrane leader peptidase
showed that the N-glycosylation efﬁciency is reduced if the
N-glycosylation site is placed less than approximately 60 residueslsevier B.V. All rights reserved.
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the prion protein [9] as well as for tissue plasminogen activator
[10]. Besides this co-translationally controlled N-glycosylation, it
is known that N-glycosylation can also occur post-translationally
within 60 amino acid residues from the C-terminus. This is depen-
dent on structural features of the glycosylated protein as it was
shown that the N-glycosylation sites of membrane dipeptidase
26 residues [11] and a mutant form of peptidylglycine a-amidating
monooxygenase 13 residues near the C-terminus [12] are efﬁ-
ciently utilised.2. Materials and methods
2.1. Materials
Monoclonal anti-human A1AT HRP-conjugated antibody from
sheep (The binding site, Schwetzingen, Germany); polyclonal rab-
bit anti-human A1AT (Dako A/S, Glostrup, Denmark); monoclonal
anti-human EPO antibody frommouse (R&D Systems, Minneapolis,
USA); monoclonal anti-human AGP antibody from mouse (Sigma,
Missouri, USA); secondary antibody peroxidase-conjugated Afﬁni-
Pure Rat Anti-Mouse IgG (Jackson ImmunoResearch Laboratories,
Suffolk, UK); Zeocin (Invitrogen; Karlsruhe, Germany); Trypsin
from bovine pancreas TPCK treated and N-Benzoyl-DL-arginine-
4-nitroanilide-hydrochloride (BAPNA) (Sigma–Aldrich, Steinheim,
Germany); AEM serum free medium, Zeocin and Lipofectamine
(Invitrogen, Karlsruhe, Germany). Other materials were purchased
from Sigma–Aldrich, Steinheim, Germany.
2.2. Construction of A1AT, EPO and AGP-GlycoTag variants
The human A1AT-cDNA was cloned from PslLoxAAT (kindly
provided by V. Sandig, ProBioGen AG, Berlin, Germany), the human
Epo-cDNA from pKex-cmvEPO (kindly provided by K. Bork, Univer-
sitätsklinikum Halle (Saale)) and the human AGP-cDNA from
hAGP-pcDNA6V5HisA (kindly provided by S. Riese, Charité – Uni-
versitätsmedizin Berlin) into pcDNA3.1 zeo (+) vector from
Invitrogen. A1AT-GT1.1 was ampliﬁed by PCR using the primers
A1AT-N-EcoRI-fw GCG GAA TTC ATG CCG TCT TCT GTC TCG TG
and A1AT-GT1.1-XbaI-rev C GCT CTA GAC GGT AGC GTT CTC
GAG TTT TTG GGT GGG ATT CAC CAC. The GlycoTags GT1.2,
GT1.3 and GT1.4 were introduced by ligation of synthetic dimeric
oligonucleotides using the former introduced XhoI and XbaI sites.
GT1.2-XhoI-XbaI-fw TC GAG GCT GCT AAC GCT ACC GT/GT1.2-
XhoI-XbaI-rev CTA GAC GGT AGC GTT AGC AGC C; GT1.
3-XhoI-XbaI-fw TC GAG GCT GCT GCT GCT AAC GCT ACC GT/
GT1.3-XhoI-XbaI-rev CTA GAC GGT AGC GTT AGC AGC AGC AGC
C; GT1.4-XhoI-XbaI-fw TC GAG GCT GCT GCT GCT GCT GCT AAC
GCT ACC GT/GT1.4-XhoI-XbaI-rev CTA GAC GGT AGC GTT AGC
AGC AGC AGC AGC AGC C; GT1.4tail-1-fw TC GAG GCT GCT GCT
GCT GCT GCT AAC GCT ACC GTC GCG GCC GCT TCT GGT GAC GTT
TGG GAC AT /GT1.4tail-1-rev CTA GAT GTC CCA AAC GTC ACC
AGA AGC GGC CGC GAC GGT AGC GTT AGC AGC AGC AGC AGC
AGC C.
2.3. Transfection of HEK293 and CHO cells and selection
HEK293 cells were cultured at 5% CO2 atmosphere and 37 C in
DMEM with glutamine supplemented with penicillin/streptomy-
cin and 10% FCS and CHO-K1 cells were cultured at 5% CO2 atmo-
sphere and 37 C in HAMS-F12 with glutamine supplemented
with penicillin/streptomycin and 10% FCS. Transfection was per-
formed with Lipofectamine according to the manufacture’s
instructions and cells were selected in the presence of 100 lg/
ml Zeocin.2.4. Expression and puriﬁcation of A1ATwt, EPOwt, AGPwt and
GlycoTag proteins
Stably transfected HEK293 or CHO-K1 cells were grown to 50%
conﬂuency washed two times with PBS and cultivated for 24 h in
AEM or OptiCHO medium, respectively. Subsequently the medium
was removed and the cells resuspended in fresh AEM or OptiCHO
medium and grown in shaking ﬂasks for ten days. The cell cultures
were centrifuged; the supernatant ﬁltrated by a 0.22 lm ﬁlter and
diluted 1:2 in water. The A1AT GlycoTag proteins were then
puriﬁed by anion-exchange chromatography (MonoQ 5/50 GL,
buffer A 0.5  PBS, buffer B 0.5  PBS + 1 M NaCl) followed by
size-exclusion chromatography (Superdex 200 10/300 GL, running
buffer 0.5  PBS).
2.5. SDS-Polyacrylamide gel electrophoresis, electroblotting and
immunostaining
Samples were prepared according to Laemmli [13] and proteins
were either directly visualized by Coomassie staining or trans-
ferred to a nitrocellulose membrane. Electrotransfer of proteins
was performed in a tank trans-blot cell (Bio-Rad, Richmond, CA,
USA) with blotting buffer (25 mM Tris, 114 mM glycine, 10% (v/v)
ethanol). After blotting, the membrane was blocked with PBS
containing 5% dry skim milk. A1AT was detected by anti-A1AT
antibody conjugated with HRP, EPO was detected with a mouse
anti-EPO antibody and AGP was detected with a mouse anti-AGP
antibody, following incubation with the secondary anti-mouse
antibody and detection carried out by the VersaDoc system
(Bio-Rad, Richmond, CA, USA). Chemiluminescence signals were
quantiﬁed using Quantity One software version 4.6.3.
2.6. A1AT-ELISA
The assay was performed in a 96-well micro plate. Each well
was coated with 100 ll of polyclonal rabbit anti-human A1AT anti-
body (0.14 lg/ml in PBS) for 16 h at 4 C. All following incubation
steps were carried out at room temperature. The wells were subse-
quently blocked with 200 ll of 1% (w/v) BSA and 0.2% (v/v) Tween
20 in PBS for 2 h. 100 ll of standard (puriﬁed recombinant human
A1ATwt) and samples were tested in triplicate and incubated for
2 h. The plate was ﬁnally washed with PBS containing 0.2% (v/v)
Tween 20. Bound A1AT was detected with 100 ll monoclonal
sheep anti-human A1AT HRP conjugated antibody.
2.7. A1AT-activity assay
The enzymatic activity of A1AT was indirectly measured by its
inhibitory activity against trypsin, while the activity of trypsin
was measured by its substrate N-Benzoyl-DL-arginine-4-nitroani-
lide-hydrochloride (BAPNA). Before measurement all samples were
adjusted to a concentration of 60 lg/ml using the A1AT-ELISA and
placed in a 96-well micro plate. A1AT (0.3 lg) was preincubated
with trypsin (0.5 lg) in a total volume of 10 ll PBS at 37 C for
10 min. Subsequently, 90 ll of BAPNA solution (2.75 mM in
100 mM NaCl, 0.01% (v/v) Triton X-100, 15 mM Tris pH 7.4) was
added. The plate was incubated at 37 C for 40 min and the absorp-
tion was measured at 405 nm. Recombinant human A1ATwt was
used as the standard.
2.8. N-glycan analysis
The A1AT GlycoTag proteins were analysed as total pools. Anal-
ysis of N-glycans of the various A1AT-GlycoTag constructs were
performed as previously described [14]. Brieﬂy, N-glycans of
puriﬁed A1ATwt and A1AT GlycoTag proteins were released by
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lysed by MALDI-TOF mass spectrometry.
3. Results
3.1. Construction of GlycoTags
In order to study the prerequisite for the usage of N-glycosyl-
ation sites at the very ends of proteins, we introduced a synthetic
N-glycosylation motif C- or N-terminally to the mature sequence
of A1AT. The basic N-glycosylation sequence used for the
N-terminally GlycoTag is composed of the amino acids Asp-Leu-
Asn-Ala-Thr-Glu (GT2.1) and for the C-terminally GlycoTag
Leu-Glu-Asn-Ala-Thr-Val (GT1.1). To avoid possible steric hin-
drance by interaction with the mature protein sequence, a spacer
sequence of two, four or six Ala residues was introduced between
the Glu- and Asn-residues and named GT1.2, GT1.3 and GT1.4,
respectively. As it has been shown previously that an N-glycosyl-
ation site at the very C-terminal end of a protein may be not
entirely used [6–9], we therefore included a tail sequence of ten
amino acids C-terminally to the GT1.4 named GT1.4tail (Fig. 1).
3.2. Expression and glycosylation efﬁciency of various GlycoTags
HEK293 and CHO cells were stably transfected with A1ATwt or
A1AT GlycoTag constructs and expressed in serum free cell
culture medium. Albumin stemming from FCS would otherwise
inﬂuence the SDS–PAGE detection of A1AT as both proteins have
similar molecular masses. In order to conﬁrm that the artiﬁcial
N-glycosylation site of the various GlycoTags is used by the glyco-
sylation machinery, cell culture supernatants were analysed by
SDS–PAGE and Western blotting using an antibody speciﬁc for
human A1AT (Fig. 2A). The A1ATwt and A1AT constructs exhibit
diffusive bands indicating that the proteins are bearing N-glycans
with distinct heterogeneity. A1ATwt shows a single band and
A1AT with the basic GlycoTag motif (GT1.1) shifted to a slightly
higher molecular mass corresponding to the six additional amino
acids of the basic GlycoTag motif. The A1AT-GT1.2 with a spacer
sequence of two Ala residues N-terminal of the N-glycosylation
motif shows the same band as A1AT-GT1.1, but also an additional
weak band with increased molecular mass indicating that some of
the A1AT-GT1.2 molecules are bearing an additional N-glycan.
The intensity of the upper band increases with the length of the
spacer sequence by four Ala-residues (A1AT-GT1.3) or six Ala
residues (A1AT-GT1.4). This shows clearly that the glycosylation
efﬁciency of the GlycoTag depends directly on the length of the
introduced spacer.Fig. 1. Schematic representation of A1AT GlycoTags constructs. GT1.1 is the basic structu
spacers of two, four and six Ala residues, respectively. GT2.1 is the N-terminal GlycoTag, inIn contrast, the N-terminally located GlycoTag-GT2.1 exhibited
no additional band, which suggests that this GlycoTag is not N-gly-
cosylated (Fig. 2A). These results were essentially the same for CHO
and HEK293 cells, but HEK293 cells exhibited a slightly increased
ratio of glycosylated to non-glycosylated GlycoTag constructs, so
that we used the HEK293 cell line for further experiments. A tail
sequence of ten amino acids was added C-terminally to the Glyco-
Tag sequence GT1.4 named GT1.4tail to increase glycosylation efﬁ-
ciency at the C-terminal and of the protein [7,8,10,11]. The
Western blot analysis shows that the tail sequence results in an en-
tirely glycosylated GlycoTag (Fig. 2A, right panel). In order to quan-
tify the degree of glycosylation, the signal intensities of the
proteins after Western blotting were detected using a gel docu-
mentation system. The degree of the glycosylated GlycoTags was
determined in relation to the non-glycosylated GlycoTags. The
introduction of the spacer between the mature protein chain and
the GlycoTag sequence increased the glycosylation efﬁciency up
to about 50%, which can be even enhanced by introduction of the
C-terminal tail sequence to nearly 100% (Fig. 2B).
In order to conﬁrm the general usage of the N-glycosylation site
introduced by the C-terminal GlycoTag-GT1.4tail, this was cloned
to two additional serum glycoproteins, namely EPO and AGP,
transfected in HEK293 and CHO-K1 cells, respectively, and the
molecular masses analysed by SDS–PAGE and speciﬁc Western blot
detection. The shift to higher molecular masses by approximately
ﬁve kDa of both proteins reveals that the N-glycosylation site of
the GT4.1tail is indeed occupied by an N-glycan (Fig. 2C).
3.3. Puriﬁcation of A1AT GlycoTag constructs
In order to analyse the activity of A1AT-GlycoTag constructs and
to determine their N-glycosylation pattern, the expression was
executed by HEK293 cells in serum free cell culture medium. This
allowed efﬁcient puriﬁcation of the expressed proteins by a two
step puriﬁcation protocol. Firstly, A1AT GlycoTag proteins were
puriﬁed by anion-exchange chromatography and A1AT containing
fractions were then puriﬁed by size-exclusion chromatography
(Supplementary Fig. 1).
3.4. Activity of A1AT GlycoTag constructs
As the introduction of the various GlycoTags may lead to
structural changes and decreased activity of the glycoprotein, the
expressed and puriﬁed A1AT GlycoTag proteins were analyzed in
regard to their ability to inhibit the protease trypsin. To this end,
A1AT was preincubated with a ratio of 3/5 with trypsin and the
activity of trypsin subsequently tested by cleavage of there of the artiﬁcially introduced N-glycosylation site. GT1.2, GT1.3 and GT1.4 contain
troduced between the signal peptide (SP) and the mature protein sequence of A1AT.
Fig. 2. Expression of A1ATwt, EPOwt, AGPwt and GlycoTag constructs. (A) Western blots showing the expression of the various A1AT GlycoTags expressed in the supernatant
of either CHO or HEK293 cells under serum-free conditions. Lane 1 shows mock transfected HEK293 (lower panel) or CHO cells (upper panel), lane 2 transfected A1ATwt,
other lanes show GlycoTag variants of A1AT as indicated. (B) Quantitation of glycosylation efﬁciency of various GlycoTags. Anti-A1AT Western blots were quantiﬁed by
luminescence detection with the VersaDoc system. The ratio of upper band (GlycoTag glycosylated) and lower band (GlycoTag unglycosylated) was calculated from at least
three different Western blots with error bares representing S.E.M. (C) Speciﬁc Western blot detection of EPO and AGP from cell culture supernatants expressed in HEK293 or
CHO-K1 cells, respectively.
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was set to 100%. As the results depend on two assays, the A1AT ELI-
SA for quantitation of A1AT and the Trypsin inhibitory assay, the
errors are relatively pronounced. Nevertheless, the activity of all
tested GlycoTag constructs are in the range of A1ATwt (Fig. 3).
3.5. N-glycan analysis of A1AT GlycoTag proteins
In order to determine the type of N-glycosylation that is added
to the GlycoTags and the possible inﬂuence of the GlycoTags on the
natural three N-glycosylation sites of A1AT, the A1AT GlycoTag
proteins were analysed for their total N-glycan composition. To
this end, the N-glycans of puriﬁed A1ATwt and A1AT GlycoTag
proteins were released using PNGase F and puriﬁed by graphite
columns. Samples were ﬁnally analysed by MALDI-TOF mass spec-
trometry after permethylation, which facilitates the detection of
sialylated N-glycans. Fig. 4 shows the relative intensities derivedFig. 3. A1AT activity analysis. A1AT activity was calculated by its inhibitory activity
to Trypsin and this activity was measured by using the chromophoric substrate
BAPNA. The activity of A1ATwt is set to 100% and all data calculated from three
independent experiments with error bares representing S.E.M.from the MALDI-TOF mass spectra. Representative MALDI-TOF
spectra are shown in Supplementary Fig. 2. The overall N-glycan
analysis shows that the composition of N-glycans is essentially
unchanged by the addition of the GlycoTags GT1.4 and GT1.4tail.
Solely, the biantennary N-glycans of the A1AT-GT1.4 and A1AT-
GT1.4tail exhibit a slightly reduced fucosylation in comparison to
A1ATwt. However, a remarkable difference was found in the N-gly-
cosylation pattern of the N-terminal A1AT-GT2.1 construct. The
expression of biantennary structures is strongly increased whereas
the tetraantennary N-glycans are almost missing and the trianten-
nary structures remain unchanged (Fig. 4). As the A1AT-GT2.1
construct does not express an additional N-glycan, the observed
changes must be attributed to a change in the native threeFig. 4. Relative intensities of the permethylated N-glycans from A1ATwt and A1AT
GlycoTags variants measured by MALDI-TOF-MS in the positive-ion mode. Bi, Tri
and Tetra represent the sum of bi, tri and tetraantennary N-glycan structures
observed irrespective of their degrees of galactosylation or sialylation. Data is
calculated from three independent analyses with error bares representing S.E.M.
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N-glycans in the N-terminal mutant A1AT-GT2.1 may be a result
of steric hindrance caused by the N-terminal inserted GlycoTag.
The N-glycosylation site N-107 is decorated with tetraantennary
besides triantennary glycans in A1ATwt in contrast to the N-glyco-
sylation sites N-70 and N-271, which do not express tetraanten-
nary N-glycans [15,16]. As the N-107 N-glycosylation site is
located in close proximity to the N-terminal end of the mature
A1AT [17], the N-terminal extension of the protein sequence of
the GlycoTag 2.1 most probably inﬂuences the processing of the
N-glycan to its tetraantennary form.
4. Discussion
It is well known that the amount and composition of N-glycans
modulate activity, function and physiological properties (i.e., circu-
latory half-life time) of therapeutically used glycoproteins. As
shown for Darbepoietin alfa, the two additional N-glycans
prolonged the circulatory half-life by threefold in comparison to
natural EPO [5]. In order to introduce additional N-glycosylation
sites without altering the sequence of the target protein, we devel-
oped a novel peptide tag constituted of an unnatural N-glycosyla-
tion site to introduce additional N-glycans to a protein. Hereby we
show that the N-glycosylation site of the smallest C-terminal Glyc-
oTag (GT1.1), constituted of only six amino acids, is hardly used.
But with longer spacer sequences, for instance with six Ala resi-
dues (GT1.4), the N-glycosylation efﬁciency increases to about
50%. This reveals that the distance between the N-glycosylation
site and the mature protein sequence is critical for the accessibility
of the N-glycosylation site to the OST complex for efﬁcient glyco-
sylation. Furthermore, by introducing a C-terminal tail sequence
of 10 amino acids (GT1.4tail), we were able to increase the N-gly-
cosylation efﬁciency of the GlycoTag 1.4tail to nearly 100%. Thus
the spacer sequence between the protein chain and the glycosyla-
tion site as well as the C-terminal ‘‘tail’’ sequence of the GlycoTags
are critical for an efﬁcient N-glycan occupancy. This efﬁcient N-gly-
cosylation of the GT1.4tail GlycoTag was shown for further serum
glycoproteins, namely EPO and AGP in the cell lines HEK293 and
CHO-K1, respectively, so that it can be concluded that the GT1.4tail
GlycoTag can be used generally in order to introduce additional
N-glycosylation sites.
As only one amino acid separates the N-glycosylation site from
the C-terminal end in GlycoTags 1.1–1.4 and only 11 amino acids
in GlycoTag 1.4tail, it can be deduced that glycosylation by the
OST complex is post-translationally executed [7–10]. In contrast
to the C-terminal GlycoTags 1.1–1.4, the N-terminal GlycoTag 2.1
introduced between the signal peptide and mature protein se-
quence is not N-glycosylated. This may be due to its near location
to the signal peptide cleavage site and/or the mature protein
sequence.
In this study, we were able to construct a synthetic C-terminal
GlycoTag that is used by the N-glycosylation machinery of mam-
malian cells and decorated with complex-type N-glycans of the
same type as the natural N-glycans of the tagged protein A1AT.
In addition, we could demonstrate that the activity of A1AT is
not inﬂuenced by adding the GlycoTags and that the GlycoTag
GT1.4tail exhibiting the best N-glycosylation efﬁciency can proba-
bly used generally for introduction of an additional N-glycosylation
site to various proteins.Acknowledgements
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